Aldosterone inhibition reduces the risk of sudden cardiac death in patients with heart failure

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 1, 2006, Pages 15-19

  Anand, Kishlay ^a   Mooss, Aryan N ^b   Mobiuddin, Syed M ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CREIGHTON UNIVERSITY   (United States)

Author keywords

Aldosterone; Aldosterone blocker; Renin anglotensin aldosterone system; Review; Sudden cardiac death; Sudden death; Ventricular arrhythmias

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANRENONE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; SPIRONOLACTONE;

CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; GYNECOMASTIA; HEART DEATH; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HORMONE ACTION; HORMONE INHIBITION; HORMONE SYNTHESIS; HUMAN; HYPERKALEMIA; IMPOTENCE; MALE SEXUAL DYSFUNCTION; MASTALGIA; MAXIMUM PERMISSIBLE DOSE; MORTALITY; NONHUMAN; PATHOGENESIS; PATIENT COUNSELING; PATIENT MONITORING; REVIEW; RISK REDUCTION; SUDDEN DEATH;

ALDOSTERONE ANTAGONISTS; ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS;

EID: 33745120159     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.001     Document Type: Review

References (35)

1. Zheng ZJ, Croft JB, Giles WH, Mensah GA. Sudden cardiac death in the United States, 1989 to 1998. Circulation 2001;104:2158-63.
2. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: epidemiology, transient risk, and intervention assessment. Ann Intern Med 1993;119:1187-97.
3. Myerburg RJ, Interian A Jr., Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol 1997;80:10F-19F.
4. Solomon SD, Zelenkofske S, McMurray JJV et al. the Valsartan in acute myocardial infarction trial I. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both; N Engl J Med 2005;352:2581-8.
5. Gorgels APM, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The Maastricht Circulatory Arrest Registry. Eur Heart J 2003;24:1204-09.
6. Zareba W, Piotrowicz K, McNitt S, Moss AJ. Implantable cardioverter-defibrillator effifacy in patients with heart failure and left ventricular dysfunction (from the MADIT II population). Am J Cardiol 2005;95:1487-91.
7. Davila DF, Nunez TJ, Odreman R, de Davila CA. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications. Int J Cardiol 2005;101:343-6.
8. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
9. Cha AJ, Malecha SE, Judge KW. Aldosterone, a new appreciation of its role in heart failure. Pharmacotherapy 2000;20:1107-15.
10. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation 1990;82:1730-6.
11. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
12. Amsterdam EA. Revised American College of Cardiology/American Heart Association guidelines for the management of heart failure. Prev Cardiol 2005;8:254-6.
13. Aronson D, Burger AJ. Neurohumoral activation and ventricular arrhythmias in patients with decompensated congestive heart failure: role of endothelin. Pacing Clin Electrophysiol 2003;26:703-10.
14. Schunkert H, Hense H, Muscholl M et al. Associations between circulating components of the renin-angiotensin-aldosterone system and left ventricular mass. Heart 1997;77:24-31.
15. Tsuji H, Venditti FJ Jr., Evans JC, Larson MG, Levy D. The associations of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol 1994;74:232-5.
16. Zennaro MC, Farman N, Bonvalet JP, Lombes M. Tissue-specific expression of alpha and beta messenger ribonucleic acid isoforms of the human mineralocorticoid receptor in normal and pathological states. J Clin Endocrinol Metab 1997;82:1345-52.
17. Robert V, Silvestre JS, Charlemagne D et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995;26:971-8.
18. Brilla CG, Zhou G, Matsubara L, Weber KT. Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994;26:809-20.
19. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertension 1992;19:221-7.
20. Petrov VV, Fagard RH, Lijnen PJ. Transforming growth factor-beta(1) induces angiotensin-converting enzyme synthesis in rat cardiac fibroblasts during their differentiation to myofibroblasts. JRAAS 2000;1:342-52.
21. Laine GA. Microvascular changes in the heart during chronic arterial hypertension. Circ Res 1988;62:953-60.
22. alil JE, Doering CW, Janicki JS, Pick R, Shroff SG, Weber KT. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ Res 1989;64:1041-50.
23. Sigel AV, Centrella M, Eghbali-Webb M. Regulation of proliferative response of cardiac fibroblasts by transforming growth factor-beta 1. J Mol Cell Cardiol 1996;28:1921-9.
24. Petrov VV, Fagard RH, Lijnen PJ. Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension 2002;39:258-63.
25. Feldman AM, Combes A, Wagner D et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35:537-44.
26. Seta Y, Shan K, Bozkurt B, Oral H, Mann DL. Basic mechanisms in heart failure: The cytokine hypothesis. J Card Fail 1996;2:243-9.
27. Hansen PR, Rieneck K, Bendtzen K. Spironolactone inhibits production of proinflammatory cytokines by human mononuclear cells. Immunology Letters 2004;91:87-91.
28. Cittadini A, Monti MG, Isgaard J et al. Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure. Cardiovasc Res 2003;58:555-64.
29. Barr CS, Lang CC, Hanson J, Arnett M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol 1995;76:1259-65.
30. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
31. Pitt B, Zannad F, Remme WJ et al. The Randomized Aldactone Evaluation Study Investigators. The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure. N Engl J Med 1999;341:709-77.
32. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
33. Buckberg GD. Sudden cardiac death after heart failure; symptomatic versus disease treatment? An editorial comment. Heart Failure Reviews 2005;9:347-51.
34. Pitt B, White H, Nicolau J et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 2005;46:425-31.
35. Priori SG, Aliot E, Blomstrom-Lundqvist C et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2001;22:1374-450.